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Many surgeons and most laypeople think that there is a
strict correlation between the size of the stomach and the
size of the meals. The term ‘‘stomach reduction’’ became a
synonym for weight loss surgeries, as if by reducing the
stomach, all meals would automatically be small.
However, there is no strict correlation between the size of
this organ and the size of meals. Some morbidly obese
patients have previously undergone total gastrectomy! If a
simple stomach reduction treated obesity, the absence of a
stomach should cause impressive weight loss; however, this
principle is not always true. On the other hand, some
patients, despite having normal-sized stomachs, feel very
satisfied with three spoonfuls of food. How can these
phenomena be explained?
The stomach is a pouch with a hole. The rate of emptying
is even more important than the size of the pouch itself. In
addition, a variety of different and complex mechanisms are
involved in the initiation and termination of a meal.
The rate of gastric emptying to the bowel is very
important. It defines the amount of nutrients that may,
through absorption, enter the blood stream, thereby altering
the blood composition and threatening the homeostasis. A
fast and intense nutrient absorption rapidly changes the
blood composition (i.e., with elevations in sugars and lipids)
and demands a quick and efficient metabolic answer.
Some refined and pre-digested elements of the modern
diet are free of fiber and completely ready for a fast
absorption. These elements have been called high-glycemic
index foods, ever since Jenkins (1) defined the concept of the
glycemic index in 1980.
In the stomach, food is mixed with acidic gastric secretions
and proteolytic enzymes. Most microbes ingested with food
are killed by acid; therefore, any contamination risk is
minimized. Large pieces of food are broken down, and the
osmolarity of the content is adjusted. The food and drink that
present the right osmolarity will leave the stomach sooner,
thereby explaining why one can drink a liter of sweet iced tea
more easily and quickly than a liter of pure water.
Additionally, the stomach adds the R factor and intrinsic
factor to allow vitamin B12 to be absorbed in the ileum.
Once these steps are complete, the stomach sends the
chyme (i.e., the food mixed with digestive secretions) to the
small bowel, where it is immediately admixed with the
biliopancreatic juices that lead to near-complete digestion
(mammals cannot digest fiber without the bacterial help of
fermentation, which occurs in the colon).
In the duodenum, the absorption of small particles is
initiated promptly, and the chyme keeps moving down-
wards as the absorption process occurs. Endogenous
glucose production is not interrupted at this stage (i.e., the
pancreatic a-cells do not suspend glucagon production).
Hypoglycemia may kill an animal in minutes, so the
proximal bowel does not have the ‘‘authority’’ to give such
an extreme order, but it can produce a less powerful one
(i.e., the proximal gut secretes glucose-dependent insulino-
tropic polypeptide, an insulinotropic agent that cannot
suppress glucagon and the endogenous production of
glucose (2-4)). At this point, satiety is not supposed to
occur. For quite obvious reasons, the proximal gut is not the
point at which food should trigger intense satiety or initiate
the suspension of glucagon production.
Nonetheless, when the distal portion of the small bowel
receives nutrients (meaning that a significant meal was
effectively consumed), the neuroendocrine L cells in the
mucosa produce hormones like glucagon-like peptide 1
(GLP-1), oxyntomodulin and polypeptide YY (PYY), which
are typical postprandial hormones (5-7). These hormones
promote the transition from the fasting state to a postprandial
state. In the fasting state, there is hunger, high levels of
glucagon, endogenous glucose production, and lipolysis. In the
typical postprandial state, an intense production of insulin,
blood clearance of glucose and lipids, lipogenesis, and a
diminution in the gastric emptying and satiety progressively
appear. They are opposite metabolic states.
GLP-1 inhibition of gastric emptying indeed outweighs its
insulinotropic effects (8). In other words, the distal intestine
stops the gastric emptying at a certain point (e.g., when
stimulated by nutrients). Therefore, the intestine defines the
functional size of the stomach.
If we suddenly eat progressively more and more refined
food, absorption becomes easier and more intense in the
proximal gut, thereby reducing the distal stimulation.
As a consequence, there may be deficiencies in the
production of distal gut hormones, like GLP-1 and PYY
(which happens in obese and type 2 diabetic patients
(9,10)), and much food may pass through stomach,
regardless of its size. If we do not have the proper
stimulation of the distal gut, a simple reduction of the
stomach may not work. Indeed, some post-surgical patients
left with 30-mL stomach pouches can still eat enough to
remain obese or at least to regain most of the lost weight
after post-operative adaptation.
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After the distal intestine is busy with digestion and
absorption, it secretes the distal gut hormones, which
impede further gastric emptying. The typical hunger is
suppressed in the brain, where there are receptors for gut
hormones. Elevated GLP-1 and insulin suppress the
production of ghrelin (a hormone that provokes hunger
and the behavior aimed at seeking food (11)).
Surprisingly, even then, superior animals (including
humans) do not stop eating. At this stage, the stomach is
not emptying well anymore, yet the animal continues eating
until the stomach is very full. GLP-1 facilitates this storage
process because it provokes a relaxation of the gastric
fundus, therefore allowing the stomach to receive more food
(12). At this point, an animal would not actively look for
food (i.e., the foraging behavior); however, if there is space
in the stomach and food available, the animal continues
eating. The ‘‘intestinal satiety’’ has already been initiated,
the typical hunger is gone, but ‘‘the gastric satiety’’ does not
appear until the stomach is completely full.
It is not hunger that motivates the animal at this point, but
gluttony. The distinction between intestinal and gastric
satiety was just created as an important didactic division
for general understanding.
Gluttony is not a sin. It is a wonderful instinct, developed
over millions of years, for times of scarcity. A wild dog that
finds food today is not certain he will find it again
tomorrow. Creating reserves may cause some fullness
today, but it may save his life in the near future.
In summary, there are two different phases of alimenta-
tion. Initially, there is hunger: the stomach empties easily
(and its size does not much matter at this point), and the
intestine is receptive. Later, the intestine is loaded, and the
distal gut hormones are produced to trigger a metabolic
response. Gastric emptying is dramatically reduced, and
GLP-1 relaxes the gastric fundus to allow further eating.
Thus, the hunger is gone, but there is gluttony. With
gluttony, the animal keeps on eating until there the stomach
is physically full, and the gas at the gastric fundus is
progressively expelled by eructation.
Therefore, after the intestinal satiety phase, it is normal to
continue eating, so an animal can take along what the bowel
cannot process immediately. The animal eats until the
stomach is full. This gastric satiety phase complements the
intestinal satiety phase. It is common to hear from patients:
‘‘Doctor, I keep on eating even when I am not hungry
anymore! I think it is anxiety!’’
Most obese patients present with an attenuated and
delayed intestinal satiety because they have a diminished
secretion of distal gut hormones after meals. Therefore, the
stopping point in gastric emptying is also delayed and the
central satiety signals are jeopardized.
In this extreme scenario, impeding someone from eating
by simply tying the digestive tract with bands, narrowing
anastomoses or reducing stomachs will create either a lean
but unhappy patient if he or she really cannot eat or a
patient who is still fat if he or she can continue to eat.
So, does the size of the stomach matter at all? Yes, it matters.
The development of this storage chamber that allows you to
‘‘overeat’’ to create storage if the nextmeal fails is very adequate
during times of scarcity. If food scarcity is suddenly substituted
by food abundance and the next meal is always there,
overeating may occur with every meal. To proportionally
reduce this organ adapts the individual to abundance. The
evolutionary data strongly support the idea that mechanisms of
food storage are found in those individuals exposed to scarcity
(e.g., a camel stocks water, a frog does not).
In the current western world, there is abundance: the food
is refined, pre-digested and quickly absorbed in the upper
bowel (i.e., high glycemic index foods are prevalent). In
these circumstances, the intestinal satiety may come too late,
and the gastric emptying is not properly diminished in time.
In this case, the size of the stomach (although over-sized for
the times of abundance) will not matter greatly, and it will
be perfectly possible for someone with a minimal stomach,
or even none, to be very fat.
Mechanical restriction and malabsorption were always
the two pillars of classic bariatric surgery. However, it is
now clear that neither of these factors is responsible for the
most beneficial effects of this type of surgery (13). Instead,
they are a primary source of post-operative problems (14).
To reach ‘‘the two satieties’’ at the optimal time and in the
absence of mechanical restriction and malabsorption is a
physiological method of approaching the epidemics of
obesity and diabetes.
In recent years, the majority of researchers in the field
recognize that the most effective models of classic bariatric
surgery work because of the hormonal changes they provoke
(13). As such, they started calling this surgical specialty
‘‘Bariatric andMetabolic Surgery.’’ Nonetheless, the procedures
are the same, and they still contain restrictive and malabsorp-
tive elements because they have been designed to include them.
New procedures, mainly developed in Brazil (15-20),
were specifically designed to selectively cause the hormonal
and metabolic corrections. By abolishing mechanical restric-
tion (21) (through the means of minimal stomachs with
narrow anastomoses or bands) and also avoiding excluded
digestive segments and malabsorption, we may reach the
‘‘Pure Metabolic Surgery.’’ It will be an evolution.
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